Pongrithsukda V, Gluck R, Suwatanapongched S, Kaewmalung P, Muyakul J
Department of Pediatrics, Maharaj Nakhon Ratchasima Hospital, Thailand.
Southeast Asian J Trop Med Public Health. 1991 Sep;22(3):347-50.
Due to the recent finding that most infants in developing countries have lost maternal antibody for measles before nine months of age, immunization of infants younger than the recommended age of nine months would help reducing the incidence of measles in these endemic areas. We conducted a trial of Edmonston-Zagreb measles vaccine which is the strain that may be more immunogenic in young infants than the widely used Schwarz strain. Forty-five infants with mean age of 25 weeks received a dose of Edmonston-Zagreb vaccine. Antibody levels were measured, using plaque neutralization test, before and about 3 months after vaccination at which mean age was 38 weeks. The seroconversion rate was 89%. Only two infants (4.4%) had immunity before vaccination. Fifteen infants (33.33%) reported some adverse reactions including fever (13.33%), rhinorrhea (8.89%), rash (4.44%) and local reactions (22.22%). All of the reactions resolved spontaneously. We conclude that Edmonston-Zagreb measles vaccine is efficacious and safe in infants aged under nine months.
由于最近发现发展中国家的大多数婴儿在9个月龄之前就已失去母体麻疹抗体，因此对低于推荐年龄9个月的婴儿进行免疫接种将有助于降低这些流行地区的麻疹发病率。我们进行了一项关于埃德蒙斯顿- Zagreb麻疹疫苗的试验，该毒株在幼儿中可能比广泛使用的施瓦茨毒株更具免疫原性。45名平均年龄为25周的婴儿接种了一剂埃德蒙斯顿- Zagreb疫苗。在接种疫苗前以及接种后约3个月（平均年龄为38周）使用空斑中和试验测量抗体水平。血清转化率为89%。只有两名婴儿（4.4%）在接种疫苗前具有免疫力。15名婴儿（33.33%）报告了一些不良反应，包括发热（13.33%）、流鼻涕（8.89%）、皮疹（4.44%）和局部反应（22.22%）。所有反应均自发消退。我们得出结论，埃德蒙斯顿- Zagreb麻疹疫苗在9个月龄以下婴儿中有效且安全。
